Transpulmonary chemoembolization and microwave ablation for recurrent or advanced non-small cell Lung Cancer.
Interventional radiology
Microwave ablation
Non-small cell lung cancer
Transpulmonary chemoembolization
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
07
05
2024
accepted:
14
10
2024
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
27
10
2024
Statut:
epublish
Résumé
To verify the treatment effect of the combination of transpulmonary chemoembolization (TPCE) and microwave ablation (MWA), targeting the treatment of recurrent or advanced non-small cell lung cancer (NSCLC). A total of 53 patients were studied and grouped according to the diameter of the largest pulmonary nodule, defined as index tumor size (ITS). Patients with an ITS > 3 cm (n = 20) were treated with TPCE and MWA. Patients with an ITS ≤ 3 cm were treated either with a combination therapy (n = 24) or MWA alone (n = 9). The treatment response, including complications and survival outcome, was then analyzed. After TPCE, there was an average ITS reduction of 0.91 cm, and 25% of patients in ITS > 3 cm were downgraded to ITS ≤ 3 cm. After TPCE, there were 12 patients (27%) with PR status and 32 (73%) with SD status. No PD patient in our case series was noted before MWA.The complication rate of MWA was significantly higher in ITS ≤ 3 cm than in ITS > 3 cm (p = 0.013). The median survival time (MST) was 26.7 months, and the time to progression was 13.2 months. The patients in the ITS ≤ 3 cm had longer MST than the others (31.6 vs. 15.8 months, p = 0.003). The significant prognostic factor was ITS > 3 cm (HR: 1.18, p = 0.02). A combination of TPCE and MWA might be feasible to control non-operable, recurrent, or advanced NSCLC.
Identifiants
pubmed: 39462003
doi: 10.1038/s41598-024-76323-y
pii: 10.1038/s41598-024-76323-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25491Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Ettinger, D. S. et al. Non-small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice guidelines in Oncology. J. Natl. Compr. Canc Netw. 20, 497–530 (2022).
doi: 10.6004/jnccn.2022.0025
pubmed: 35545176
Mouli, S. K., Kurilova, I., Sofocleous, C. T. & Lewandowski, R. J. The role of percutaneous image-guided thermal ablation for the treatment of Pulmonary malignancies. AJR Am. J. Roentgenol. 209, 740–751 (2017).
doi: 10.2214/AJR.17.18368
pubmed: 28657845
Bourgouin, P. P. et al. Comparison of percutaneous image-guided microwave ablation and cryoablation for Sarcoma Lung metastases: a 10-Year experience. AJR Am. J. Roentgenol. 218, 494–504 (2022).
doi: 10.2214/AJR.21.26551
pubmed: 34612679
Vogl, T. J. et al. Thermal ablation of lung tumors: focus on microwave ablation. Rofo. 189, 828–843 (2017).
doi: 10.1055/s-0043-109010
pubmed: 28511267
Murphy, M. C., Wrobel, M. M., Fisher, D. A., Cahalane, A. M. & Fintelmann, F. J. Update on image-guided thermal lung ablation: Society guidelines, Therapeutic Alternatives, and Postablation Imaging findings. AJR Am. J. Roentgenol. 219, 471–485 (2022).
doi: 10.2214/AJR.21.27099
pubmed: 35319908
Lindemayr, S., Lehnert, T., Korkusuz, H., Hammerstingl, R. & Vogl, T. J. Transpulmonary chemoembolization: a novel approach for the treatment of unresectable lung tumors. Tech. Vasc Interv Radiol. 10, 114–119 (2007).
doi: 10.1053/j.tvir.2007.09.010
pubmed: 18070689
Pohlen, U. et al. Chemoembolization of lung metastases–pharmacokinetic behaviour of carboplatin in a rat model. Anticancer Res. 27, 809–815 (2007).
pubmed: 17465206
Pohlen, U. et al. Chemoembolization with carboplatin of the lung. Feasibility and toxicity in a pig model. Anticancer Res. 27, 1503–1508 (2007).
pubmed: 17595768
Vogl, T. J. et al. Transvenous pulmonary chemoembolization (TPCE) for palliative or neoadjuvant treatment of lung metastases. Eur. Radiol. 29, 1939–1949 (2019).
doi: 10.1007/s00330-018-5757-8
pubmed: 30338364
Vogl, T. J., Mekkawy, A. & Thabet, D. B. Intravascular Treatment Techniques for Locoregional Therapies of Lung Tumors. Rofo. (2023).
Gadaleta, C. D. et al. Unresectable lung malignancy: combination therapy with segmental pulmonary arterial chemoembolization with drug-eluting microspheres and radiofrequency ablation in 17 patients. Radiology. 267, 627–637 (2013).
doi: 10.1148/radiol.12120198
pubmed: 23249572
Wolf, F. J. et al. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. 247, 871–879 (2008).
doi: 10.1148/radiol.2473070996
pubmed: 18372457
Vogl, T. J., Shafinaderi, M., Zangos, S., Lindemayr, S. & Vatankhah, K. Regional chemotherapy of the lung: transpulmonary chemoembolization in malignant lung tumors. Semin Intervent Radiol. 30, 176–184 (2013).
doi: 10.1055/s-0033-1342959
pubmed: 24436534
pmcid: 3709942
Vogl, T. J. et al. Diffusion-weighted MR imaging of primary and secondary Lung Cancer: predictive value for response to Transpulmonary Chemoembolization and Transarterial Chemoperfusion. J. Vasc Interv Radiol. 31, 301–310 (2020).
doi: 10.1016/j.jvir.2019.08.027
pubmed: 31899107
Gruber-Rouh, T. et al. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study. BMC Cancer. 18, 188 (2018).
doi: 10.1186/s12885-018-4099-x
pubmed: 29444653
pmcid: 5813391
Nour-Eldin, N. A. et al. Ablation therapy of non-colorectal cancer lung metastases: retrospective analysis of tumour response post-laser-induced interstitial thermotherapy (LITT), radiofrequency ablation (RFA) and microwave ablation (MWA). Int. J. Hyperth. 33, 820–829 (2017).
Blackmon, S. H. et al. Technical and safety performance of CT-guided percutaneous microwave ablation for lung tumors: an ablate and resect study. J. Thorac. Dis. 13, 6827–6837 (2021).
doi: 10.21037/jtd-21-594
pubmed: 35070367
pmcid: 8743408
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Filippiadis, D. K. et al. Cirse Quality Assurance Document and standards for classification of complications: the cirse classification system. Cardiovasc. Intervent Radiol. 40, 1141–1146 (2017).
doi: 10.1007/s00270-017-1703-4
pubmed: 28584945
Prentice, R. L. et al. The analysis of failure times in the presence of competing risks. Biometrics. 34, 541–554 (1978).
doi: 10.2307/2530374
pubmed: 373811
Akhan, O., Güler, E., Akıncı, D., Çiftçi, T. & Köse, I. Radiofrequency ablation for lung tumors: outcomes, effects on survival, and prognostic factors. Diagn. Interv Radiol. 22, 65–71 (2016).
doi: 10.5152/dir.2015.14378
pubmed: 26611111
Healey, T. T., March, B. T., Baird, G. & Dupuy, D. E. Microwave ablation for lung neoplasms: a retrospective analysis of long-term results. J. Vasc Interv Radiol. 28, 206–211 (2017).
doi: 10.1016/j.jvir.2016.10.030
pubmed: 27993505
Zheng, A. et al. Major complications after lung microwave ablation: a single-center experience on 204 Sessions. Ann. Thorac. Surg. 98, 243–248 (2014).
doi: 10.1016/j.athoracsur.2014.03.008
pubmed: 24793688
Kashima, M. et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am. J. Roentgenol. 197, W576–580 (2011).
doi: 10.2214/AJR.11.6408
pubmed: 21940529
Vogl, T. J. et al. A comparison between 915 MHz and 2450 MHz microwave ablation systems for the treatment of small diameter lung metastases. Diagn. Interv Radiol. 24, 31–37 (2018).
doi: 10.5152/dir.2018.17017
pubmed: 29317376
pmcid: 5765926
Ierardi, A. M., Coppola, A., Lucchina, N. & Carrafiello, G. Treatment of lung tumours with high-energy microwave ablation: a single-centre experience. Med. Oncol. 34, 5 (2017).
doi: 10.1007/s12032-016-0861-6
pubmed: 27900591
Rangamuwa, K. et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 10, 2842–2857 (2021).
doi: 10.21037/tlcr-20-1075
pubmed: 34295682
pmcid: 8264311
Ni, Y. et al. Multicentre study of microwave ablation for pulmonary oligorecurrence after radical resection of non-small-cell lung cancer. Br. J. Cancer. 125, 672–678 (2021).
doi: 10.1038/s41416-021-01404-y
pubmed: 34131307
pmcid: 8405665
Feng, K. & Lu, Y. Clinical analysis of systemic chemotherapy combined with microwave ablation in the treatment of lung cancer. Asian J. Surg. 45, 1107–1112 (2022).
doi: 10.1016/j.asjsur.2021.08.013
pubmed: 34509354
Huang, Y. et al. Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer. Front. Oncol. 12, 938827 (2022).
doi: 10.3389/fonc.2022.938827
pubmed: 36091128
pmcid: 9459232